Sojournix Stock

sojournixpharma.comHealthcareFounded: 1900Funding to Date: $71.39MM

Sojournix is a clinical stage biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of women’s health and neuroendocrine disorders.

Register for Details

For more details on financing and valuation for Sojournix, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Sojournix.

Register Today

Team

Management Team

Scott Rakestraw
Board Member & Co-Founder
Daniel Grau
Co-Founder, President, Chief Executive Officer, and Director

Board Members

Martin Freed MD
Peter Kolchinsky
Daniel Grau
Scott Rakestraw
Aaron Davis
Tavistock Group
Peter Lanciano

Other companies like Sojournix in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$298.33MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$327.39MM
Sector
 
 
Sector
Last Round Est. Valuation
$500MM

News

Sojournix, a developer of new medicines for the treatment of women's health and neuroendocrine disorders, completed a $44m Series C financing